ilf3 Antibody

Introduction to ILF3 Antibody

ILF3 antibodies target the protein encoded by the ILF3 gene, which plays dual roles in transcriptional regulation and post-transcriptional RNA stabilization . These antibodies are critical for:

• Detecting ILF3 expression in tissues (e.g., cancer vs. normal)

• Characterizing subcellular localization (nuclear vs. cytoplasmic)

• Validating ILF3 knockdown/overexpression in experimental models

Cancer Biology

• Gastric Cancer (GC):

  • ILF3 protein overexpression was observed in 72.5% of GC tissues vs. 13.75% in adjacent mucosa (χ²=48.89; P<0.001) .

  • siRNA-mediated ILF3 suppression reduced GC cell viability by 38.6% (BGC823) and 41.8% (SGC7901) at 48 hours :

  Cell Line	Viability (% vs Control)	G0/G1 Phase Increase	p21 Upregulation
  BGC823	61.4%	+18.7%	3.2-fold mRNA
  SGC7901	58.2%	+15.9%	2.8-fold mRNA

Immunology

• Dendritic Cell Regulation:
  ILF3 antibodies confirmed its role as a negative regulator of DC maturation, with NF110's DZF domain being critical for suppressing innate immune responses .

Angiogenesis

ILF3 antibodies helped identify its pro-angiogenic function through VEGF-induced mRNA stabilization in endothelial cells .

Antibody Performance

• Western Blot Sensitivity:

  • Proteintech's 19887-1-AP detects ILF3 at dilutions up to 1:16,000 in HeLa/K562 lysates .

  • Abcam's ab133354 distinguishes NF110 from NF90 in Raji/K562 cells .

IHC Optimization

• Antigen Retrieval:
  Citrate buffer (pH 6.0) or TE buffer (pH 9.0) recommended for human tissue IHC .

Functional Insights from Antibody-Based Studies

• Domain Mapping: Nuclear localization sequences (NLS) in ILF3 are required for immune suppression, while the DZF domain mediates cell cycle regulation .

• RNA Interaction: Antibody-linked IP experiments revealed ILF3's binding to pro-angiogenic mRNA targets like VEGF and ICAM1 .